Table 5.
Selected ongoing early phase clinical trials in adult patients.
| Agent | Trial/Tumor type | Regimen (single agent unless otherwise specified) |
|---|---|---|
| 2-deoxyglucose Dichloroacetate | Pilot/Stage IV radiosensitive tumors 1/Recurrent head and neck cancer 1/Advanced malignancies 1/CNS 1/Head and neck cancer |
DCA + cisplatin + radiation |
| CPI-613 | 1/Relapsed/refractory AML 1 & 2/Advanced malignancies 1/Small cell lung cancer 1/Myelodysplastic syndrome 1/Metastatic pancreatic cancer 1/Metastatic bile duct cancer |
CPI-613 + cytarabine + mitoxantrone CPI-613 + FOLFIRINOX |
| AZD-3965 Mangafodipir ARQ-501 STA-4783 |
1/Advanced malignancies 2/Metastatic colorectal 1/Advanced solid tumors 1/Relapsed/refractory AML 2/Recurrent or persistent ovarian epithelial, fallopian, primary peritoneal |
FOLFOX +/− mangafodipir STA-4783 + paclitaxel |
| Arsenic Trioxide | 1/NSCLC 1/Myelofibrosis 1/Chronic myelogenous leukemia 1 & 2/Malignant glioma 2/Relapsed/refractory AML 1/Acute promyelocytic leukemia 2/Hepatocellular carcinoma 2/Small cell lung cancer |
ATO + icotinib ATO +/− ascorbic acid ATO + TKI ATO + temozolomide + radiation ATO + ATRA + GO TACE +/− ATO |
| ATN-224 | 1/Metastatic non-squamous NSCLC 1/Esophageal cancer 2/Breast cancer |
ATN-224 + Carboplatin/pemetrexed ATN-224 + chemoradiation |
| Imexon Elspar | 2/Relapsed follicular and aggressive lymphoma 1/Hematologic malignancies 1 & 2/Acute lymphoblastic leukemia |
|
| Oncaspar ADI-PEG 20 |
T-cell lymphoma 1/Mesothelioma, NSCLC 1/Prostate cancer, NSCLC 1/HER2-breast cancer 1/Metastatic melanoma 2/Acute myelogenous leukemia 2/Non-Hodgkin lymphoma |
Oncaspar + dexamethasone ADI-PEG 20 + pemetrexed + cisplatin ADI-PEG 20 + docetaxel ADI-PEG 20 + doxorubicin ADI-PEG 20 + cisplatin |
| EGCG | 1/Head and neck cancer 2/Amyloidosis |
EGCG + erlotinib |
| AG-120 | 1/Advanced solid tumors, glioma 1/Advanced hematologic malignancy |
|
| AG-221 E7070 |
1/Advanced hematologic malignancy 2/Relapsed AML, MDS |
E7070 + idarubicin + cytarabine |
ADI: Arginine deiminase; AML: Acute myeloid leukemia; ATO: Arsenic trioxide; EGCG: Epigallocatechin gallate; MDS: Myelodysplastic syndrome.